Prediction of Appearance of Late Cutaneous Side Effects After RadioTherapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03060226

Acronym

PAESCART

Enrollment

Registered

2017-02-23

Start date

2017-02-09

Completion date

2018-12-20

Last updated

2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Merkel Carcinoma, Radiotherapy Side Effect

Brief summary

Search for blood predictive marker (s) for cutaneous radiosensitivity

Interventions

DIAGNOSTIC_TESTblood sample

Search of blood predictive marker (s)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient treated with surgery and radiotherapy (RT) for histologically proven Merkel carcinoma * Previous radiotherapy treatment completed for at least 6 months * Absence of prior treatment by chemotherapy or hormonotherapy * Patient over 18 years of age * Patient affiliated to a social security system * Informed consent signed

Exclusion criteria

* Presence of another evolutionary cancer * Re-irradiation in the same area * Absence of available dosimetry data * Patient under guardianship or curatorship or safeguard of justice

Design outcomes

Primary

Measure	Time frame	Description
Identification and dosage of blood predictive marker(s)	1 blood sample at inclusion	Concentration of IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-α, TGF-β, IL-13, IL-17 and CRP

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026